Chinese Medicine in the Battle Against Obesity and Metabolic Diseases.
Chinese Medicine in the Battle Against Obesity and Metabolic Diseases.
复制标题
中医对抗肥胖和代谢性疾病
DOI：
10.3389/fphys.2018.00850
复制
发表时间：
2018
影响因子：
4
通讯作者：
Ma X
中科院分区：
文献类型：
--
作者：
Xu L;Zhao W;Wang D;Ma X
肥胖是一种由遗传、环境以及能量摄入和消耗失衡等多种因素共同影响所导致的慢性疾病。由于生活方式的改变，现代社会中肥胖的发生率迅速上升，同时普通人群患代谢综合征的风险也在加剧，包括糖尿病、肝脂肪变性、心血管疾病以及某些类型的癌症。尽管肥胖已成为一个严重的全球性公共卫生危害，但仍然缺乏有效且安全的治疗肥胖的药物。中医药在中国已经有几千年的实际应用历史，并在治疗各种疾病方面积累了大量的一线经验。与成分明确、分子机制清晰的西医相比，中医药由动植物的复杂成分组成，并根据整体症状和经验来用药。由于它们之间存在根本差异，中医药和西医曾经被认为是不可调和的。然而，如今先进的分离技术以及对中医药活性成分分子层面认识的加深，正在逐渐弥合两者之间的差距，使得能够在西式范式下识别用于药物开发的中医药活性成分。因此，中医药研究开辟了一条新的治疗途径，在对抗肥胖方面显示出巨大潜力，尽管也存在挑战。在这篇综述中，我们重点介绍了六种来自中医药的关键候选物质，包括青蒿素、姜黄素、雷公藤红素、辣椒素、小檗碱和人参皂苷，回顾它们在代谢领域的最新发现，特别关注它们在治疗肥胖和代谢疾病方面的治疗效果和分子机制。此外，我们还讨论了将现代中医药引入西方制药行业所面临的转化挑战和前景。
Obesity is a multi-factor chronic disease caused by the mixed influence of genetics, environments and an imbalance of energy intake and expenditure. Due to lifestyle changes, modern society sees a rapid increase in obesity occurrence along with an aggravated risk of metabolic syndromes in the general population, including diabetes, hepatic steatosis, cardiovascular diseases and certain types of cancer. Although obesity has become a serious worldwide public health hazard, effective and safe drugs treating obesity are still missing. Traditional Chinese medicine (TCM) has been implicated in practical use in China for thousands of years and has accumulated substantial front line experience in treating various diseases. Compared to western medicine that features defined composition and clear molecular mechanisms, TCM is consisted with complex ingredients from plants and animals and prescribed based on overall symptoms and collective experience. Because of their fundamental differences, TCM and western medicine were once considered irreconcilable. However, nowadays, sophisticated isolation technologies and deepened molecular understanding of the active ingredients of TCM are gradually bridging the gap between the two, enabling the identification of active TCM components for drug development under the western-style paradigms. Thus, studies on TCM open a new therapeutic avenue and show great potential in the combat against obesity, though challenges exist. In this review, we highlight six key candidate substances derived from TCM, including artemisinin, curcumin, celastrol, capsaicin, berberine and ginsenosides, to review their recent discoveries in the metabolic field, with special focus on their therapeutic efficacy and molecular mechanisms in treating obesity and metabolic diseases. In addition, we discuss the translational challenges and perspectives in implementing modern Chinese medicine into the western pharmaceutical industry.
登录
查看更多内容
影响因子：
5.2
作者：
Boss O;Farmer SR
通讯作者：
Farmer SR
DOI：
10.18632/aging.100521
发表时间：
2012-12
期刊：
Aging
影响因子：
--
作者：
Halicka HD;Zhao H;Li J;Lee YS;Hsieh TC;Wu JM;Darzynkiewicz Z
通讯作者：
Darzynkiewicz Z
DOI：
10.1097/med.0b013e328337a81f
发表时间：
2010-04
期刊：
Current opinion in endocrinology, diabetes, and obesity
影响因子：
--
作者：
Cypess AM;Kahn CR
通讯作者：
Kahn CR
雷公藤红素诱导的 Nur77 与 TRAF2 相互作用通过促进线粒体泛素化和自噬减轻炎症
影响因子：
16
作者：
Hu M;Luo Q;Alitongbieke G;Chong S;Xu C;Xie L;Chen X;Zhang D;Zhou Y;Wang Z;Ye X;Cai L;Zhang F;Chen H;Jiang F;Fang H;Yang S;Liu J;Diaz-Meco MT;Su Y;Zhou H;Moscat J;Lin X;Zhang XK
通讯作者：
Zhang XK
影响因子：
5.3
作者：
Cui, M.;Honore, P.;Faltynek, C. R.
通讯作者：
Faltynek, C. R.